exs73565
Relapsed or Refractory B-cell Malignancies
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Phase 1
—
Rating in progress
exs73565 in Relapsed or Refractory B-cell Malignancies is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.
Methodology v0.2 · Active